PD-L1 expression in human cancers and its association with clinical outcomes. PMID: 27574444
Non-cytomembrane PD-L1: An atypical target for cancer. PMID: 34174446
Emerging role of PD-L1 modification in cancer immunotherapy. PMID: 34522452
PD-L1: expression regulation. PMID: 37228770
Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. PMID: 35386715
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1. PMID: 36220994
PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. PMID: 34190579
PD-L1 expression in sarcomas: An immunohistochemical study and review of the literature. PMID: 34656856
Inhibitory Effect of PD-1/PD-L1 and Blockade Immunotherapy in Leukemia. PMID: 34238150
The Prognostic and Therapeutic Value of PD-L1 in Glioma. PMID: 30687086
L1-CAM as a target for treatment of cancer with monoclonal antibodies. PMID: 20044598
Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. PMID: 33178688
PD-L1 in circulating exosomes of Merkel cell carcinoma. PMID: 34994009
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. PMID: 34204509
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. PMID: 35625917
L1 (LINE-1) retrotransposon diversity differs dramatically between mammals and fish. PMID: 14698614
Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma. PMID: 33447446
An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. PMID: 33896308
PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. PMID: 36028784
Homophilic interaction of the L1 family of cell adhesion molecules. PMID: 22573111
Ubiquitin C-terminal hydrolase-L1 (UCH-L1) as a therapeutic and diagnostic target in neurodegeneration, neurotrauma and neuro-injuries. PMID: 28434268
Mitochondrial and Neuronal Dysfunctions in L1 Mutant Mice. PMID: 35457156
Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage ("SEE") Signal to Facilitate the Elimination of "Cold, Non-Responsive" Low PD-L1-Expressing Tumors by PD-L1 Blockade. PMID: 31783532
The function of neuropilin/L1 complex. PMID: 12613546
Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours. PMID: 33475525
The recent evolution of human L1 retrotransposons. PMID: 16093692
Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study. PMID: 36152566
On the Link Between L1-PCA and ICA. PMID: 27337712
PD-L1 blockade enhances anti-tumor efficacy of NK cells. PMID: 30377572
Soluble PD-L1 Expression After Intravenous Treatment of Cancer Patients With Selenite in Phase I Clinical Trial. PMID: 35720000
The Cell Adhesion Molecule L1 Interacts with Methyl CpG Binding Protein 2 via Its Intracellular Domain. PMID: 35408913
The cell adhesion molecule L1: species- and cell-type-dependent multiple binding mechanisms. PMID: 9084132
Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data. PMID: 36067541
Cell adhesion molecule L1 interacts with the chromo shadow domain of heterochromatin protein 1 isoforms α, β, and ɣ via its intracellular domain. PMID: 34859928
Epstein-Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma. PMID: 33804064
PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3. PMID: 33363153
Human and mouse PD-L1: similar molecular structure, but different druggability profiles. PMID: 33437940
Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer. PMID: 35721177
Revisiting the proteolytic processing of cell adhesion molecule L1. PMID: 32986867
Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response., PMID:15188075
[Significance of polypeptide antigen of HCVE2/NS1 relative conservation region in detection of anti-HCV]., PMID:12759957
Expression and purification of E2/NS1 protein of hepatitis C virus and detection of anti-E2/NS1 antibodies in chronic liver disease patients., PMID:12595764
Identification of human hepatocyte protein(s), which binds specifically to the recombinant envelope-2/non-structural-1 protein of hepatitis C virus., PMID:12191777
Antibody response to E2 glycoprotein induced in mice by immunization with plasmid DNA containing sequence derived from a Chinese genotype III/2a isolate of hepatitis C virus., PMID:11593587
Molecular design and immunogenicity studies of multiple antigenic peptide corresponding to envelope glycoprotein hypervariable region 1 of hepatitis C virus., PMID:11503045
Predominance of antibodies to hepatitis C virus envelope proteins in various disease statuses of hepatitis C., PMID:11394572
[Expression of glycoprotein hepatitis C virus in mammalian cell and application of purified protein for detection of antibody against E2 in hepatitis C patients]., PMID:10715790
Antibody response to E2/NS1 hepatitis C virus protein in patients with acute hepatitis C., PMID:9076628
Significance of anti-E2 in the diagnosis of HCV infection in patients on maintenance hemodialysis: anti-E2 is frequently detected among anti-HCV antibody-negative patients., PMID:8959633
Lack of correlation between different hepatitis C virus screening and confirmatory assays., PMID:8793841
Quantitative analysis of antibody to hepatitis C virus envelope 2 glycoprotein in patients with chronic hepatitis C virus infection., PMID:8621173
Fraction-specific populations of the hypervariable region of the hepatitis C virus in a patient with cryoglobulinemia., PMID:7595420
Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses., PMID:7815542
The serology of hepatitis C virus (HCV) infection: antibody crossreaction in the hypervariable region 1., PMID:7503672
Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees., PMID:7941335
[Evolution of hepatitis C virus (HCV) viremia and adaptation of HCV in persistent infection in patients with acute hepatitis]., PMID:7521430
Analysis of hepatitis C virus capsid, E1, and E2/NS1 proteins expressed in insect cells., PMID:8212557
Hypervariable 5'-terminus of hepatitis C virus E2/NS1 encodes antigenically distinct variants., PMID:7689636
[Hepatitis C]., PMID:8345654
Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein., PMID:7680297
[Expression of hepatitis C virus genome]., PMID:7681882
Expression of HCV E2/NS1 protein as a fusion protein with maltose binding protein: detection of anti-E2/NS1 antibody in chronic liver disease., PMID:7686121
Expression of MBP-HCV NS1/E2 fusion protein in E. coli and detection of anti-NS1/E2 antibody in type C chronic liver disease., PMID:1314578
For research use only. Not for human or drug use.
